Perspectives in therapy for hepatitis C

Sandro Vento, Francesca Cainelli, Zelalem Temesgen

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Background: Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Objective: To review papers published or presented at recent international meetings showing the results of trials of new anti-HCV drugs. Methods: Literature search using the terms 'antivirals', 'interferon', 'pegylated interferon', 'ribavirin', 'polymerase inhibitors', 'protease inhibitors', 'cyclophilin inhibitors' and 'hepatitis C virus'. Search of abstracts containing the same terms in the title and presented at the American Association for the Study of Liver Diseases 2007 and at the European Association for the Study of the Liver 2008 meetings. Results/conclusion: Preliminary results of Phase II studies of new compounds look promising, although side effects are higher than with current standard of treatment.

Original languageEnglish
Pages (from-to)1635-1639
Number of pages5
JournalExpert Opinion on Investigational Drugs
Issue number11
Publication statusPublished - Nov 1 2008


  • Alb-IFN
  • Antivirals
  • Boceprevir
  • Cyp inhibitors
  • Hepatitis C
  • Peg-IFN
  • Polymerase inhibitors
  • Protease inhibitors
  • Ribavirin
  • Telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Perspectives in therapy for hepatitis C'. Together they form a unique fingerprint.

Cite this